← Back to Clinical Trials
Recruiting Phase 4 NCT05604222

NCT05604222 Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05604222
Status Recruiting
Phase Phase 4
Sponsor Shachi Tyagi
Condition Urgency Urinary Incontinence
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2023-03-05
Primary Completion 2026-05-31

Trial Parameters

Condition Urgency Urinary Incontinence
Sponsor Shachi Tyagi
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 120
Sex FEMALE
Min Age 60 Years
Max Age N/A
Start Date 2023-03-05
Completion 2026-05-31
Interventions
Mirabegron 50 MGBrief Behavioral Treatment for Insomnia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Urgency urinary incontinence (UUI) is common in older people and vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will investigate the role of adding behavioral sleep intervention to the standard pharmacotherapy in treatment of UUI among older adults, and the brain mechanisms involved in continence by evaluating brain changes. This will expand the current knowledge of how the sleep affects bladder control, and better characterize the brain mechanisms in maintaining continence.

Eligibility Criteria

Inclusion Criteria: * ambulatory women aged 60+ years * urgency incontinence or urge-predominant mixed incontinence (able to differentiate between stress symptoms-cough, laugh, exercise-and leakage following the sudden onset of a strong urge to void that is difficult to defer during questioning on telephone screening) occurring at least five times weekly for ≥ 3 months despite treatment for reversible causes * nocturia ≥2 each night * subjects with current or previous use of anticholinergic medications will be considered for the study if willing to go through a washout period of at least 4 weeks of duration Exclusion Criteria: * contraindication to any of the drugs used (e.g., mirabegron, prophylactic antibiotics) * cognitive impairment (MOCA score \<24 or inability to accurately complete a voiding diary, perform a 24-hour pad test, reliably take daily medication, or comply with fMRI testing) * prior treatment with intradetrusor onabotulinum toxin or sacral neuromodulation. * spinal co

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology